Flowonix Medical Inc. Announces US Market Launch of the Prometra® Programmable Intrathecal Drug Infusion Pump New Implantable Pump Provides Important New Options for Physicians Treating Chronic Pain Patients
MOUNT OLIVE, N.J., April 11, 2013 /PRNewswire/ -- Flowonix Medical Inc., a medical device company focused on providing advanced implantable drug delivery solutions, announced today the US launch of the Prometra programmable intrathecal pump. The Prometra pump provides important new enhancements for physicians who treat patients in chronic pain through the delivery of preservative-free morphine, Infumorph®. The Prometra pump offers improved accuracy and longevity compared to currently available programmable pumps, both important factors in providing enhanced therapy to chronic pain patients.
"Given the increased concern regarding the abuse of oral narcotics, programmable pumps offer clinicians an important option for treating patients suffering from chronic pain. In addition to the economic and clinical advantages of implantable pump therapy, the Prometra pump contains innovative technology for very accurate drug delivery and increased device longevity," stated Tim Deer, MD, Clinical Professor of Anesthesiology at West Virginia University. The Prometra pump uses a patented dual-gated valve drug delivery mechanism resulting in very accurate dosing of medication and due to few moving parts significantly improves the longevity of the pump.
Programmable intrathecal pumps are implanted in the body and deliver a tiny amount of medication directly to the intrathecal space around the spinal column. This allows physicians to reduce the amount of medication needed daily by the patient.
"The programmable intrathecal pump is a therapy whose efficacy in treating patients in chronic pain has been established for over 25 years. This therapy has demonstrated consistent clinical benefits for patients suffering from chronic pain, including chronic back pain, a debilitating disease costing millions of dollars in lost productivity and reducing the ability of patients to manage their activities of daily living," stated Dr. Yeshvant A. Navalgund, pain management physician from Greensburg, Pa.
The Prometra infusion pump offers a new design compared to infusion pumps on the market, which helps make the pump highly accurate in dosing.
"We are pleased to offer pain management physicians and patients a dual-gated valve pump versus the currently available peristaltic pump," stated Steve Adler, CEO of Flowonix Medical Inc. "Physicians are looking for options to the negative effects of high doses of oral narcotics for the management of pain in chronic pain patients. In a multicenter clinical study, the Prometra pump system demonstrated accurate, safe, and effective delivery of intrathecal medication.1 This should reduce the amount of oral medication necessary to manage pain, reduce side effects associated with oral narcotics, and, as we see in new cost effectiveness studies, reduce the cost associated with drug delivery compared to oral narcotics."
Flowonix Medical Inc. (www.flowonix.com), headquartered in Mt. Olive, NJ, is dedicated to working with healthcare professionals to help ease suffering associated with chronic pain and allow patients to reclaim their lives through innovation and therapy advancements. The strategic business goal of Flowonix Medical Inc. is to become the leading implantable drug delivery company in the world. Founded in 2005, Flowonix Medical Inc. received approval to conduct its first clinical trial in 2007 on the Prometra programmable implantable pump. The company received approval by the FDA to market the Prometra in 2012. Flowonix Medical Inc. has been granted multiple patents, and is focused on working closely with physicians to rapidly improve the capabilities of implantable drug delivery and management systems.
For more information see the Flowonix web site at: http://www.flowonix.com.
1 Indicated for Infumorph®
Contact: Steven Adler 973-426-9229
SOURCE Flowonix Medical Inc.